Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial

IMPORTANCE: Drug development for metastatic castration-resistant prostate cancer has been limited by a lack of clinically relevant trial end points short of overall survival (OS). Radiographic progression-free survival (rPFS) as defined by the Prostate Cancer Clinical Trials Working Group 2 (PCWG2)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Rathkopf, Dana E., Beer, Tomasz M., Loriot, Yohann, Higano, Celestia S., Armstrong, Andrew J., Sternberg, Cora N., de Bono, Johann S., Tombal, Bertrand, Parli, Teresa, Bhattacharya, Suman, Phung, De, Krivoshik, Andrew, Scher, Howard I., Morris, Michael J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2018
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5885186/
https://ncbi.nlm.nih.gov/pubmed/29522174
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.5808
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados